# A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise

> **NCT06777238** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Gan & Lee Pharmaceuticals.** · enrollment: 274 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** GZR18
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06777238
- **Lead sponsor:** Gan & Lee Pharmaceuticals.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-16
- **Primary completion:** 2026-08-07
- **Final completion:** 2027-03-10
- **Target enrollment:** 274 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06777238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06777238, "A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06777238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*